While many Americans rely on generic drugs as an inexpensive way to treat common ailments, common essential medications can vary in quality from manufacturer to manufacturer and even batch to batch of, especially when a drug goes generic. The team at New Haven-based Valisure saw a market opportunity and developed techniques and technology to make sure that each batch of medicine they distribute has been tested for many of the most important properties, like dosage, dissolution and contaminants.
Our speaker at WHIPgroup’s Meetup on Tuesday, June 16, is David Light, CEO of Valisure. A repeat entrepreneur who’s worked for several successful biotech startups. David is a repeat entrepreneur who’s worked for several successful biotech startups. He will share his insights into the current world of healthcare and the opportunities presenting themselves to biotech leaders with the background and drive to get things done.
Recently, WHIPGROUP engaged in an arbitration that included a five day hearing in the City. Here are some thoughts about why arbitration is different (not clearly better or worse) than litigation. Venue The AAA arbitral [Read More…]
WHIPGroup previously filed a Motion to Dismiss a patent infringement suit filed against its client TomTom in the Western District of Texas. Rather than opposing WHIPGroup’s motion to dismiss, Plaintiff MDSP Technologies LLC voluntarily dismissed [Read More…]
WHIPgroup succeeded in having anticipation and indefiniteness rejections overturned by the Patent Trial and Appeal Board (PTAB). The claimed invention relates to a sequencing station that manages both sequencing and restacking tasks. The Examiner had [Read More…]